NCT01813591View on ClinicalTrials.gov

A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

November 30, 2015

Conditions
Chronic Migraine
Interventions
DRUG

H.P. Acthar Gel

Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)

Trial Locations (4)

14226

Dent Neurologic Institute, Amherst

65807

Clinvest/A Division of Banyan Group, Inc., Springfield

75231

Baylor University Medical Center, Dallas

89502

Renown Institute of Neurosciences, Reno

Sponsors
All Listed Sponsors
lead

Dent Neuroscience Research Center

OTHER

NCT01813591 - A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines | Biotech Hunter | Biotech Hunter